What is the projected market valuation of the Fungal Testing Kits Market by 2035?

The projected market valuation for the Fungal Testing Kits Market by 2035 is 28.06 USD Billion. Read More

What was the overall market valuation of the Fungal Testing Kits Market in 2024?

The overall market valuation of the Fungal Testing Kits Market in 2024 was 10.79 USD Billion. Read More

What is the expected CAGR for the Fungal Testing Kits Market during the forecast period 2025 - 2035?

The expected CAGR for the Fungal Testing Kits Market during the forecast period 2025 - 2035 is 9.08%. Read More

Which diagnostic method segment is projected to have the highest valuation by 2035?

The Molecular Testing segment is projected to reach a valuation of 8.0 USD Billion by 2035. Read More

What are the key players in the Fungal Testing Kits Market?

Key players in the Fungal Testing Kits Market include Thermo Fisher Scientific, Roche Diagnostics, and Abbott Laboratories. Read More

How does the valuation of the Candida indication segment change from 2024 to 2035?

The valuation of the Candida indication segment is expected to increase from 2.2 USD Billion in 2024 to 5.5 USD Billion by 2035. Read More

What is the projected valuation for the Skin Biopsy sample type segment by 2035?

The projected valuation for the Skin Biopsy sample type segment by 2035 is 5.0 USD Billion. Read More

Which end user segment is anticipated to have the highest growth by 2035?

The Pharmaceutical Companies end user segment is anticipated to grow to 8.21 USD Billion by 2035. Read More

What was the valuation of the Blood sample type segment in 2024?

The valuation of the Blood sample type segment in 2024 was 2.5 USD Billion. Read More

How does the market for Rapid Diagnostic Tests compare to other diagnostic methods by 2035?

The market for Rapid Diagnostic Tests is projected to reach 7.06 USD Billion by 2035, indicating strong growth compared to other diagnostic methods. Read More

Fungal Testing Kits Market

ID: MRFR/HC/25942-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Fungal Testing Kits Market Research Report By Sample Type (Blood, Urine, Cerebrospinal Fluid, Skin Biopsy, Nail clippings), By Indication (Aspergillosis, Candida, Cryptococcus, Histoplasmosis, Blastomycosis), By Diagnostic Method (Culture, Serology, Molecular Testing, Microscopy, Rapid Diagnostic Tests), By End User (Hospitals and Clinics, Diagnostic Laboratories, Research Institutes, Veterinary Clinics, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Sample Type (USD Billion)
  1. 4.1.1 Blood
  2. 4.1.2 Urine
  3. 4.1.3 Cerebrospinal Fluid
  4. 4.1.4 Skin Biopsy
  5. 4.1.5 Nail Clippings
2. 4.2 Healthcare, BY Indication (USD Billion)
  1. 4.2.1 Aspergillosis
  2. 4.2.2 Candida
  3. 4.2.3 Cryptococcus
  4. 4.2.4 Histoplasmosis
  5. 4.2.5 Blastomycosis
3. 4.3 Healthcare, BY Diagnostic Method (USD Billion)
  1. 4.3.1 Culture
  2. 4.3.2 Serology
  3. 4.3.3 Molecular Testing
  4. 4.3.4 Microscopy
  5. 4.3.5 Rapid Diagnostic Tests
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals and Clinics
  2. 4.4.2 Diagnostic Laboratories
  3. 4.4.3 Research Institutes
  4. 4.4.4 Veterinary Clinics
  5. 4.4.5 Pharmaceutical Companies
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche Diagnostics (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Abbott Laboratories (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 BD (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 bioMerieux (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hologic (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Cepheid (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Agilent Technologies (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 PerkinElmer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY SAMPLE TYPE
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY SAMPLE TYPE
8. 6.8 CANADA MARKET ANALYSIS BY INDICATION
9. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY INDICATION
14. 6.14 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY SAMPLE TYPE
17. 6.17 UK MARKET ANALYSIS BY INDICATION
18. 6.18 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY INDICATION
22. 6.22 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY INDICATION
26. 6.26 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY SAMPLE TYPE
29. 6.29 ITALY MARKET ANALYSIS BY INDICATION
30. 6.30 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY INDICATION
34. 6.34 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY INDICATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY SAMPLE TYPE
42. 6.42 CHINA MARKET ANALYSIS BY INDICATION
43. 6.43 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY SAMPLE TYPE
46. 6.46 INDIA MARKET ANALYSIS BY INDICATION
47. 6.47 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY INDICATION
51. 6.51 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY INDICATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY INDICATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY INDICATION
63. 6.63 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY INDICATION
67. 6.67 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY INDICATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY INDICATION
76. 6.76 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY INDICATION
80. 6.80 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY INDICATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY INDICATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY INDICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Sample Type (USD Billion, 2025-2035)

Blood
Urine
Cerebrospinal Fluid
Skin Biopsy
Nail Clippings

Healthcare By Indication (USD Billion, 2025-2035)

Aspergillosis
Candida
Cryptococcus
Histoplasmosis
Blastomycosis

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

Culture
Serology
Molecular Testing
Microscopy
Rapid Diagnostic Tests

Healthcare By End User (USD Billion, 2025-2035)

Hospitals and Clinics
Diagnostic Laboratories
Research Institutes
Veterinary Clinics
Pharmaceutical Companies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”